Literature DB >> 10854698

A PPARgamma mutant serves as a dominant negative inhibitor of PPAR signaling and is localized in the nucleus.

J Berger1, H V Patel, J Woods, N S Hayes, S A Parent, J Clemas, M D Leibowitz, A Elbrecht, R A Rachubinski, J P Capone, D E Moller.   

Abstract

The peroxisomal proliferator-activated receptors (PPARs) are members of the nuclear receptor superfamily that act as ligand-activated transcription factors. PPARgamma plays a critical role in regulating adipocyte differentiation and lipid metabolism. Recently, thiazolidinedione (TZD) and select non-TZD antidiabetic agents have been identified as PPARgamma agonists. To further characterize this receptor subclass, a mutant hPPARgamma lacking five carboxyl-terminal amino acids was produced (hPPARgamma2Delta500). In COS-1 cells transfected with PPAR-responsive reporter constructs, the mutant receptor could not be activated by a potent PPARgamma agonist. When cotransfected with hPPARgamma2 or hPPARalpha, hPPARgamma2Delta500 abrogated wild-type receptor activity in a dose-responsive manner. hPPARgamma2Delta500 was also impaired with respect to binding of a high-affinity radioligand. In addition, its conformation was unaffected by normally saturating concentrations of PPARgamma agonist as determined by protease protection experiments. Electrophoretic mobility shift assays demonstrated that hPPARgamma2Delta500 and hPPARgamma2 both formed heterodimeric complexes with human retinoidxreceptor alpha (hRXRalpha) and could bind a peroxisome proliferator-responsive element (PPRE) with similar affinity. Therefore, hPPARgamma2Delta500 appears to repress PPAR activity by competing with wild type receptor to dimerize with RXR and bind the PPRE. In addition, the mutant receptor may titrate out factors required for PPAR-regulated transcriptional activation. Both hPPARgamma2 and hPPARgamma2Delta500 localized to the nucleus of transiently transfected COS-1 cells as determined by immunofluorescence using a PPARgamma-specific antibody. Thus, nuclear localization of PPARgamma occurs independently of its activation state. The dominant negative mutant, hPPARgamma2Delta500, may prove useful in further studies to characterize PPAR functions both in vitro and in vivo

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10854698     DOI: 10.1016/s0303-7207(00)00211-2

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  13 in total

Review 1.  The interrelationship between bone and fat: from cellular see-saw to endocrine reciprocity.

Authors:  H Sadie-Van Gijsen; N J Crowther; F S Hough; W F Ferris
Journal:  Cell Mol Life Sci       Date:  2012-11-21       Impact factor: 9.261

2.  Interaction with MEK causes nuclear export and downregulation of peroxisome proliferator-activated receptor gamma.

Authors:  Elke Burgermeister; Dana Chuderland; Tamar Hanoch; Markus Meyer; Mordechai Liscovitch; Rony Seger
Journal:  Mol Cell Biol       Date:  2006-11-13       Impact factor: 4.272

3.  Cross-Talk between PPARgamma and Insulin Signaling and Modulation of Insulin Sensitivity.

Authors:  Anna Leonardini; Luigi Laviola; Sebastio Perrini; Annalisa Natalicchio; Francesco Giorgino
Journal:  PPAR Res       Date:  2010-02-23       Impact factor: 4.964

4.  The PPARgamma2 A/B-domain plays a gene-specific role in transactivation and cofactor recruitment.

Authors:  Anne Bugge; Lars Grøntved; Mads M Aagaard; Rehannah Borup; Susanne Mandrup
Journal:  Mol Endocrinol       Date:  2009-03-12

5.  A functional peroxisome proliferator-activated receptor-gamma ligand-binding domain is not required for adipogenesis.

Authors:  Christopher J Walkey; Bruce M Spiegelman
Journal:  J Biol Chem       Date:  2008-07-11       Impact factor: 5.157

6.  Tumor necrosis factor-alpha induces caspase-mediated cleavage of peroxisome proliferator-activated receptor gamma in adipocytes.

Authors:  Adilson Guilherme; Gregory J Tesz; Kalyani V P Guntur; Michael P Czech
Journal:  J Biol Chem       Date:  2009-03-25       Impact factor: 5.157

7.  Molecular Mechanisms and Genome-Wide Aspects of PPAR Subtype Specific Transactivation.

Authors:  Anne Bugge; Susanne Mandrup
Journal:  PPAR Res       Date:  2010-08-31       Impact factor: 4.964

Review 8.  Revisiting PPARγ as a target for the treatment of metabolic disorders.

Authors:  Sun-Sil Choi; Jiyoung Park; Jang Hyun Choi
Journal:  BMB Rep       Date:  2014-11       Impact factor: 4.778

9.  Skp2 regulates subcellular localization of PPARγ by MEK signaling pathways in human breast cancer.

Authors:  Hongge Cheng; Jie Meng; Guisheng Wang; Yuming Meng; Yu Li; Dong Wei; Chunyun Fu; Kaifeng Deng; Aiguo Shen; Huimin Wang; Shengming Dai
Journal:  Int J Mol Sci       Date:  2013-08-09       Impact factor: 5.923

10.  Serum regulates adipogenesis of mesenchymal stem cells via MEK/ERK-dependent PPARgamma expression and phosphorylation.

Authors:  Ling Wu; Xiaoxiao Cai; Hai Dong; Wei Jing; Yuanding Huang; Xingmei Yang; Yao Wu; Yunfeng Lin
Journal:  J Cell Mol Med       Date:  2009-02-20       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.